Evaluation of curative effect of bevacizumab combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion

Abstract

Objective To evaluate the clinical effect of bevacizumab combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion. Methods 73 cases of non-small cell lung cancer with malignant pleural effusion in our hospital from May 2011 to April 2015 were chosen.And all patients were randomly divided into the study group (n=37) and the control group (n=36). The patients in control group were treated with cisplatin, while the patients in study group were treated with cisplatin and bevacizumab.The level of vascular endothelial growth factor (VEGF) before and after treatment, quality of life score, drug toxicity, and clinical efficacy between two groups were compared. Results After treatment for one week, two weeks, three weeks, VEGF level in two groups was significantly lower than that before treatment (P 0.05). Conclusions Bevacizumab and cisplatin are used in treating the patients with malignant pleural effusion caused by non-small cell lung cancer, VEGF level in pleural effusion is well controlled, and life quality of the patients is significantly improved, drug toxicity is low, the effect is significant, worthy of promotion. Key words: Non-small cell lung cancer; Pleural effusion, malignant; Bevacizumab; Cisplatin; Clinical effect